The patient populations for neuropathic and nociceptive pain are large, and are driven by separate disease trends that necessitate pain relief; across the seven major markets in 2005 it was estimated that 37.6m individuals suffered from neuropathic pain and 170.1m suffered from nociceptive pain.
The major constituents of the neuropathic pain market are lower back pain, neuralgia/fibromyalgia, diabetic neuropathic pain and pain associated with multiple sclerosis. The nociceptive pain market is driven by the prevalence of the major indications of arthritic pain, particularly osteoarthritis and rheumatoid arthritis, post-operative pain, cancer-related pain and HIV-related pain.
Current management of pain is mostly pharmacological consisting of the use of opioids, non-opioids and non-steroidal anti-inflammatory drugs (NSAIDs), as well as adjuvant therapies such as anti-depressants and anti-convulsants.
Just some of the key findings of the report...
- Within the pain therapy market there remains a substantial unmet need for drugs with improved efficacy and superior side-effect profiles, however there are few novel drugs in the pipeline and companies are heavily dependent on reformulations of existing drugs targeting better drug delivery, more convenient dosing schedules and specific patient populations.
- Over the 2001-05 period, the global pain market expanded at a CAGR of 7.9%, accounting for a net growth in sales of $9,571m. While the pain market has experienced several years of continuous growth, over 2004-05 sales dropped by 7.0% due to the withdrawal from the market of COX-II inhibitors, Vioxx and Bextra for safety reasons. Sales in this drug class plummeted by 66.2% in 2005.
- Currently the pain market is led by the anti-convulsant class, hich accrued sales of $11,574m in 2005 with the majority of revenue being derived from off-label use. Although the anti-convulsant class will maintain its leading position through 2010, future growth in the pain market will be driven by a small number of blockbuster drugs and the re-uptake of COX-II inhibitors
- Pfizers current dominance of the pain market is forecast to continue through 2011 due to the evolving success of its blockbuster drug, Celebrex and the recent launch of Lyrica, which promises market success comparable to its predecessor, Neurontin.
"The most prevalent tumor-related nociceptive cancer pain syndrome is bone pain. The spine is the most common site of bone metastases, which results in back pain as a highly prevalent problem among cancer sufferers..."